Conversely, patients diagnosed with NPM1-mutated AML, especially when belonging to more favorable risk subgroups according to ELN classification [10], could potentially benefit from intensive remission induction and consolidation chemotherapeutic approaches only, without firm indication to receive upfront allogeneic HSCT, unless for cases with FLT3-ITD positivity, relapsed/refractory disease or persistently elevated MRD levels [20]. This evidence concerns the gene FLT3 and acute myeloid leukemia.